Atea Pharmaceuticals (AVIR) Projected to Post Earnings on Monday

Atea Pharmaceuticals (NASDAQ:AVIR - Get Free Report) is expected to post its Q1 2025 quarterly earnings results after the market closes on Monday, May 12th. Analysts expect the company to announce earnings of ($0.41) per share for the quarter.

Atea Pharmaceuticals (NASDAQ:AVIR - Get Free Report) last announced its quarterly earnings data on Thursday, March 6th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.05). On average, analysts expect Atea Pharmaceuticals to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Atea Pharmaceuticals Price Performance

Shares of AVIR stock traded down $0.04 during trading hours on Friday, reaching $2.72. The company had a trading volume of 372,498 shares, compared to its average volume of 303,478. Atea Pharmaceuticals has a 1-year low of $2.60 and a 1-year high of $4.15. The firm has a market cap of $232.77 million, a price-to-earnings ratio of -1.31 and a beta of 0.17. The company has a 50 day moving average of $2.93 and a 200 day moving average of $3.12.

Analyst Upgrades and Downgrades

Several brokerages have commented on AVIR. Morgan Stanley lowered their target price on shares of Atea Pharmaceuticals from $6.20 to $6.00 and set an "equal weight" rating for the company in a research note on Friday, April 11th. William Blair reaffirmed an "outperform" rating on shares of Atea Pharmaceuticals in a research note on Friday, March 7th.

Atea Pharmaceuticals Company Profile

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.